IE43768B1 - Oximes - Google Patents

Oximes

Info

Publication number
IE43768B1
IE43768B1 IE567/76A IE56776A IE43768B1 IE 43768 B1 IE43768 B1 IE 43768B1 IE 567/76 A IE567/76 A IE 567/76A IE 56776 A IE56776 A IE 56776A IE 43768 B1 IE43768 B1 IE 43768B1
Authority
IE
Ireland
Prior art keywords
formula
group
compound
oxime
pharmaceutically acceptable
Prior art date
Application number
IE567/76A
Other languages
English (en)
Other versions
IE43768L (en
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of IE43768L publication Critical patent/IE43768L/xx
Publication of IE43768B1 publication Critical patent/IE43768B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IE567/76A 1975-03-20 1976-03-18 Oximes IE43768B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (2)

Publication Number Publication Date
IE43768L IE43768L (en) 1976-09-20
IE43768B1 true IE43768B1 (en) 1981-05-20

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
IE567/76A IE43768B1 (en) 1975-03-20 1976-03-18 Oximes

Country Status (27)

Country Link
US (1) US4085225A (cg-RX-API-DMAC10.html)
JP (1) JPS6026776B2 (cg-RX-API-DMAC10.html)
AR (2) AR211011A1 (cg-RX-API-DMAC10.html)
AT (1) AT340895B (cg-RX-API-DMAC10.html)
AU (1) AU505358B2 (cg-RX-API-DMAC10.html)
BE (1) BE839744A (cg-RX-API-DMAC10.html)
CA (1) CA1076142A (cg-RX-API-DMAC10.html)
CH (4) CH626057A5 (cg-RX-API-DMAC10.html)
DD (1) DD128332A5 (cg-RX-API-DMAC10.html)
DE (1) DE2610886A1 (cg-RX-API-DMAC10.html)
DK (1) DK144942C (cg-RX-API-DMAC10.html)
ES (1) ES446192A1 (cg-RX-API-DMAC10.html)
FI (1) FI61875C (cg-RX-API-DMAC10.html)
FR (1) FR2304336A1 (cg-RX-API-DMAC10.html)
GB (1) GB1535226A (cg-RX-API-DMAC10.html)
GR (1) GR60052B (cg-RX-API-DMAC10.html)
HU (1) HU171030B (cg-RX-API-DMAC10.html)
IE (1) IE43768B1 (cg-RX-API-DMAC10.html)
IL (1) IL49238A (cg-RX-API-DMAC10.html)
IT (1) IT1063064B (cg-RX-API-DMAC10.html)
MX (1) MX9203723A (cg-RX-API-DMAC10.html)
NL (1) NL7503310A (cg-RX-API-DMAC10.html)
PL (3) PL100052B1 (cg-RX-API-DMAC10.html)
SE (1) SE410312B (cg-RX-API-DMAC10.html)
SU (3) SU635867A3 (cg-RX-API-DMAC10.html)
YU (1) YU39345B (cg-RX-API-DMAC10.html)
ZA (1) ZA761434B (cg-RX-API-DMAC10.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
EP0759299B1 (en) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentiation of serotonin response
IN182588B (cg-RX-API-DMAC10.html) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (cg-RX-API-DMAC10.html) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
EP1276478A2 (en) * 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
NZ532033A (en) * 2001-10-12 2006-11-30 Azevan Pharmaceuticals Inc 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
AU2006239920A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
SG163588A1 (en) 2005-07-08 2010-08-30 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT2491038T (pt) 2009-10-23 2016-07-14 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
WO2014178064A2 (en) * 2013-04-03 2014-11-06 Zcl Chemicals Limited "an improved process for the preparation of fluvoxamine maleate"
PL3104847T3 (pl) 2014-02-07 2021-07-05 Támogatott Kutatócsoportok Irodája Nowe zastosowanie związków agonistycznych receptora sigma-1
MX2021005502A (es) 2014-03-28 2023-01-16 Azevan Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades neurodegenerativas.
KR102559922B1 (ko) 2016-03-10 2023-07-25 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
MA46898A (fr) 2016-11-24 2019-10-02 Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag Compositions pour la conservation d'organes
BR112020005107A2 (pt) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. composições e métodos para o tratamento de lesão cerebral
KR20220049526A (ko) 2019-07-19 2022-04-21 바이오엑셀 테라퓨틱스 인코포레이티드 비-진정성 덱스메데토미딘 치료 양생법
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
BE839744A (fr) 1976-09-20
AU1214776A (en) 1977-09-22
CH629761A5 (de) 1982-05-14
AR211011A1 (es) 1977-10-14
CH629477A5 (de) 1982-04-30
SU620206A3 (ru) 1978-08-15
DK144942B (da) 1982-07-12
IT1063064B (it) 1985-02-11
HU171030B (hu) 1977-10-28
FR2304336B1 (cg-RX-API-DMAC10.html) 1979-09-28
ZA761434B (en) 1977-10-26
DD128332A5 (de) 1977-11-09
CH629184A5 (de) 1982-04-15
DE2610886A1 (de) 1976-10-07
SU635867A3 (ru) 1978-11-30
AU505358B2 (en) 1979-11-15
IL49238A (en) 1978-08-31
PL100052B1 (pl) 1978-08-31
GR60052B (en) 1978-04-04
GB1535226A (en) 1978-12-13
IE43768L (en) 1976-09-20
SE7603341L (sv) 1976-09-21
PL100614B1 (pl) 1978-10-31
DE2610886C2 (cg-RX-API-DMAC10.html) 1987-09-24
CA1076142A (en) 1980-04-22
FI61875C (fi) 1982-10-11
JPS51125345A (en) 1976-11-01
FI760699A7 (cg-RX-API-DMAC10.html) 1976-09-21
DK144942C (da) 1982-12-06
ATA195476A (de) 1977-05-15
NL7503310A (nl) 1976-09-22
ES446192A1 (es) 1977-10-01
YU39345B (en) 1984-10-31
IL49238A0 (en) 1976-05-31
SU645559A3 (ru) 1979-01-30
AT340895B (de) 1978-01-10
JPS6026776B2 (ja) 1985-06-25
US4085225A (en) 1978-04-18
MX9203723A (es) 1992-07-01
FR2304336A1 (fr) 1976-10-15
CH626057A5 (cg-RX-API-DMAC10.html) 1981-10-30
SE410312B (sv) 1979-10-08
PL101951B1 (pl) 1979-02-28
DK115976A (da) 1976-09-21
FI61875B (fi) 1982-06-30
AR211153A1 (es) 1977-10-31
YU71476A (en) 1982-10-31

Similar Documents

Publication Publication Date Title
IE43768B1 (en) Oximes
EP0170213B1 (en) Glutarimide antianxiety and antihypertensive agents
SK285165B6 (sk) Tetrahydropyridoétery, farmaceutický prostriedok s ich obsahom a ich použitie
US4575508A (en) 2-Substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines, and their use as antiarrhythmic agents
JPS63295589A (ja) 生理活性物質ｋ−２５２の誘導体
JPH03170481A (ja) 置換ピリミドベンズイミダゾール誘導体
RU2138501C1 (ru) Имидазопиридиназолидиноны, их соли и лекарственное средство
US4081551A (en) Oxime ethers having anti-depressive activity
HU182070B (en) Process for producing phenyl-piperazine derivatives
US4086361A (en) Aminoethyl oximes having anti-depressive activity
IE902788A1 (en) 2,3-Dihydro-1-(pyridinylamino)-indoles, a process for their preparation and their use as medicaments
EP0315112B1 (en) Novel amide compounds
HK24194A (en) Pyrrolo[1,2-a][4,1]benzoxazepines, process for their preparation, pharmaceutical compositions containing these compounds and therapeutical use
KR100382998B1 (ko) 6-메톡시-1h-벤조트리아졸-5-카르복사미드유도체,그제조방법및그것을함유하는의약조성물
US4060631A (en) Aminoethyl oxime ethers having anti-depressive activity
US4081552A (en) Oxime ethers having anti-depressive activity
US3262978A (en) O-arylamino-and-aralkyl-amino-alkylhydroxyl-amines
CN101307043A (zh) 6,8-二羟甲基白杨素和6,8-二羟甲基醚白杨素及其制备方法与药物用途
GB2100261A (en) Aminophenylalkylamine derivatives, a process for their preparation and their use as pharmaceuticals
HU184965B (en) Process for producing phenyl-piperazine derivatives of anti-agression activity
WO1997040046A1 (en) Benzoquinolizine derivatives and medicinal compositions
EP0084292A1 (en) N,N-disubstituted alkenamides and phenylalkenamides, processes for their production and their use as pharmaceuticals
FI74004C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara piperazinylpyrido/2,3-b/- och -/3,4-b/ pyrazinderivat.
JPS6342625B2 (cg-RX-API-DMAC10.html)
JPH0533950B2 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
MK9A Patent expired